Proteasome inhibitors as therapeutics

A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma

2003 • 2,642 citations

Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma

2005 • 2,457 citations

The ubiquitinproteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB

1994 • 2,124 citations

The ubiquitin-proteasome proteolytic pathway

1994 • 1,778 citations

The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.

2001 • 1,520 citations

Proteasome inhibitors: a novel class of potent and effective antitumor agents.

1999 • 1,447 citations

The proteasome: a suitable antineoplastic target

2004 • 1,189 citations

Proteasome inhibitors: from research tools to drug candidates

2001 • 1,159 citations

Phase I Trial of the Proteasome Inhibitor PS-341 in Patients With Refractory Hematologic Malignancies

2002 • 771 citations

The development of proteasome inhibitors as anticancer drugs

2004 • 768 citations

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

2002 • 759 citations

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

2004 • 758 citations

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

2003 • 721 citations

Potent and selective inhibitors of the proteasome: Dipeptidyl boronic acids

1998 • 674 citations

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

2002 • 670 citations

Proteasome inhibitors disrupt the unfolded protein response in myeloma cells

2003 • 597 citations

Phase II Clinical Experience With the Novel Proteasome Inhibitor Bortezomib in Patients With Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma

2004 • 589 citations

Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B

1996 • 582 citations

Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition.

2001 • 544 citations

The Proteasome, a Novel Protease Regulated by Multiple Mechanisms

1999 • 540 citations

Phase II Study of Proteasome Inhibitor Bortezomib in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

2004 • 531 citations

The proteasome: a novel target for cancer chemotherapy

2002 • 530 citations

Activation of the cell death program by inhibition of proteasome function

1997 • 494 citations

The proteasome inhibitor PS-341 in cancer therapy.

1999 • 475 citations

Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications

2002 • 467 citations

A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies.

2002 • 446 citations

Phase I Trial of the Proteasome Inhibitor Bortezomib in Patients With Advanced Solid Tumors With Observations in Androgen-Independent Prostate Cancer

2004 • 440 citations

Preferential induction of apoptosis for primary human leukemic stem cells

2002 • 424 citations

Biologic sequelae of nuclear factor–κB blockade in multiple myeloma: therapeutic applications

2002 • 382 citations

Development of the Proteasome Inhibitor PS-341

2002 • 364 citations

Inhibition of Constitutive NF-κB Activation in Mantle Cell Lymphoma B Cells Leads to Induction of Cell Cycle Arrest and Apoptosis

2003 • 325 citations

Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor.

1998 • 277 citations

26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer

2001 • 263 citations

Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341.

2000 • 205 citations

Phase I Study of Bortezomib in Refractory or Relapsed Acute Leukemias

2004 • 196 citations

Phase II Trial of Bortezomib for Patients With Advanced Renal Cell Carcinoma

2004 • 192 citations

Inhibition of proteasome function induces programmed cell death in proliferating endothelial cells

2000 • 156 citations

Intracellular regulation of tumor necrosis factor–related apoptosis-inducing ligand–induced apoptosis in human multiple myeloma cells

2002 • 155 citations

Increased sensitivity of CLL‐derived lymphocytes to apoptotic death activation by the proteasome‐specific inhibitor lactacystin

1999 • 145 citations

Phase II Trial of PS-341 in Patients With Renal Cell Cancer: A University of Chicago Phase II Consortium Study

2003 • 140 citations

New insights into the mechanisms and importance of the proteasome in intracellular protein degradation.

1997 • 140 citations

Phase II Study of the Proteasome Inhibitor Bortezomib (PS-341) in Patients with Metastatic Neuroendocrine Tumors

2004 • 132 citations

p53-dependent apoptosis induced by proteasome inhibition in mammary epithelial cells

2001 • 78 citations

Role of interleukin 6 in the growth of myelomaderived cell lines

1992 • 74 citations

Ubiquitin-Proteasome System and Increased Sensitivity of B-CLL Lymphocytes to Apoptotic Death Activation

2000 • 45 citations

Concepts in the use of TRAIL/Apo2L: an emerging biotherapy for myeloma and other neoplasias

2001 • 34 citations

Bortezomib vs. dexamethasone in relapsed multiple myeloma: A phase 3 randomized study

2004 • 32 citations

Effects of bortezomib (PS-341) on NF-κB activation in peripheral blood mononuclear cells (PBMCs) of advanced non-small lung cancer (NSCLC) patients: A phase II/pharmacodynamic trial

2004 • 31 citations

Phase (ph) 2 study of bortezomib ± docetaxel in previously treated patients (pts) with advanced non-small cell lung cancer (NSCLC): Preliminary results

2004 • 19 citations